Further, the mice injected with AKT2 KO cells showed a survival benefit relative to NT-injected mice (Figure 5H), which is consistent with the previous results, indicating that AKT2 depletion delays the onset of metastatic disease and overall survival. The gene discussed is AKT2; the disease is metastatic neoplasm.